NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Alpha Tau Medical Ltd. (DRTS) Stock Analysis

Alpha Tau Medical Ltd. (DRTS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

DRTS

$15.03

+$0.41 (+2.80%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DRTS with… →

DRTS Key Statistics

As of Sep 4, 2026
Trading
Open
$14.69
Previous Close
$14.62
Day's Range
14.43–15.17
52-Week Range
3.43–15.17
Volume
749.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.21
Valuation
Market Cap
$1.39B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.07
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$42.63M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
92.48M
1-Year Return
+330.66%
Dividend and dates
Earnings Date
November 19, 2026estimated
Avg Volume
686.46K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DRTS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+203.64%
2025+59.68%
2024+2.99%
2023−5.35%
2022−67.62%
2021 (partial year)−2.77%

As of September 4, 2026.

DRTS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$42.63M—
2024$0.00−$31.75M—
2023$0.00−$29.16M—
2022$0.00−$33.76M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$42.29M−$42.63M—
2024$0.00—−$36.04M−$31.75M—
2023$0.00—−$35.68M−$29.16M—
2022$0.00—−$32.14M−$33.76M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DRTS Valuation vs Biotechnology Median

Median of 656 stocks
MetricDRTSBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Alpha Tau Medical Ltd. (DRTS) at $1.39B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 121.

The most recent close on file for DRTS is $15.03, dated September 4, 2026. That is +$0.41 (+2.80%) against the previous close. The 52-week range on file runs from $3.43 to $15.17. The latest close sits 338.19% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $42.63M. The reported profit margin is 0%. Trailing earnings per share are −1.07.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +330.66%. Measured over 5 years, that is +8.77% a year compounded. Beta against the wider market is reported at 1.21. Daily returns over the trailing 5 years annualize to a volatility of 80.24%.

Growth & Income

No dividend is on file for DRTS.

The strongest complete calendar year on file is 2025 at +59.68%; the weakest is 2022 at −67.62%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +203.64% year to date.

Peer Comparison

Alpha Tau Medical Ltd. (DRTS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alpha Tau Medical Ltd. DRTS $1.39B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Alpha Tau Medical Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

Visit website →